The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to SIM0505 for the treatment of women with platinum resistant ovarian cancer (PROC) Phase 1 data for SIM0505 to be presen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results